Dabrafenib and its use in the Treatment of Metastatic Melanoma

References

• Gray-Schopfer V , WellbrockC , MaraisR . Melanoma biology and new targeted therapy . Nature445 ( 7130 ), 851 – 857 ( 2007 ).
   PubMed Web of Science ®Google Scholar
• Thompson JF , ScolyerRA , KeffordRF . Cutaneous melanoma . Lancet365 ( 9460 ), 687 – 701 ( 2005 ).
   PubMed Web of Science ®Google Scholar
• Siegel R , MaJ , ZouZ , JemalA . Cancer statistics, 2014 . CA Cancer J. Clin.64 ( 1 ), 9 – 29 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Marshall C . Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation . Cell Elsevier80 ( 2 ), 179 – 185 ( 1995 ).
   Google Scholar
• Heidorn SJ , MilagreC , WhittakerSet al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF . Cell140 ( 2 ), 209 – 221 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Siroy AE , BolandGM , MiltonDRet al. Beyond BRAF(V600): clinical mutation panel testing by next-generation sequencing in advanced melanoma . J. Invest. Dermatol.135 ( 2 ), 508 – 515 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Hauschild A , GrobJ-J , DemidovLVet al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, Phase III randomised controlled trial . Lancet380 ( 9839 ), 358 – 365 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• King AJ , ArnoneMR , BleamMRet al. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions . PLoS ONE8 ( 7 ), e67583 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Menzies AM , LongGV , MuraliR . Dabrafenib and its potential for the treatment of metastatic melanoma . Drug Des. Devel. Ther.6 , 391 – 405 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Hatzivassiliou G , SongK , YenIet al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth . Nature464 ( 7287 ), 431 – 435 ( 2010 ).
   PubMed Web of Science ®Google Scholar
• Gentilcore G , MadonnaG , MozzilloNet al. Effect of dabrafenib on melanoma cell lines harbouring the BRAF(V600D/R) mutations . BMC Cancer13 ( 1 ), 17 ( 2013 ).
   PubMedGoogle Scholar
• Falchook GS , LongGV , KurzrockRet al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a Phase 1 dose-escalation trial . Lancet379 ( 9829 ), 1893 – 1901 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• European Medicines Agency . Summary of product characteristics: Tafinlar1 – 64 . www.ema.europa.eu
   Google Scholar
• Lee CI , MenziesAM , HayduLEet al. Features and management of pyrexia with combined dabrafenib and trametinib in metastatic melanoma . Melanoma Res.24 ( 5 ), 468 – 474 ( 2014 )
   PubMed Web of Science ®Google Scholar
• Center for Drug Evaluation and Research . Approved Drugs – trametinib and dabrafenib . Center for Drug Evaluation and Research; 2014 .
   Google Scholar
• Hauschild A , GrobJJ , DemidovLVet al. An update on BREAK3, a Phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E positive mutation metastatic melanoma (MM) . Presented at : ASCO Annual Meeting 2013.Chicago, IL, USA , 31 May–4 June2013 .
   Google Scholar
• Grob JJ , DemidovL , JouaryT , GutzmerR , MillwardM . An update on overall survival (OS) and follow-on therapies in BREAK-3, a Phase III, randomized trial: dabrafenib (D) vs dacarbazine (DTIC) in patients (pts) with BRAF V600E mutation-positive metastatic melanoma. Society for Melanoma Research . Presented at : European Society for Medical Oncology (ESMO) 2014 Congress.Madrid, Spain , 26–30 September2014 .
   Google Scholar
• Hauschild A , GrobJ-J , DemidovLVet al. An update on overall survival (OS) and follow-on therapies in BREAK-3, a Phase III, randomized trial: dabrafenib (D) vs. dacarbazine (DTIC) in patient (pts) with BRAF V600E mutation-positive metastatic melanoma (MM) . Presented at : European Society for Medical Oncology (ESMO) 2014 Congress.Madrid, Spain , 26–30 September2014 .
   Google Scholar
• Flaherty KT , InfanteJR , DaudAet al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations . N. Engl. J. Med.367 ( 18 ), 1694 – 1703 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Long GV , StroyakovskiyD , GogasHet al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma . N. Engl. J. Med.29 , 371 , 1877 – 1888 ( 2014 ).
   Google Scholar
• Robert C , KaraszewskaB , SchachterJet al. Improved overall survival in melanoma with combined dabrafenib and trametinib . N. Engl. J. Med.372 ( 1 ), 30 – 39 ( 2015 ).
   PubMed Web of Science ®Google Scholar
• Chapman PB , HauschildA , RobertCet al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation . N. Engl. J. Med.364 ( 26 ), 2507 – 2516 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Larkin J , AsciertoPA , DrénoBet al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma . N. Engl. J. Med.371 ( 20 ), 1867 – 1876 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Long GV , TrefzerU , DaviesMAet al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, Phase 2 trial . Lancet Oncol.13 ( 11 ), 1087 – 1095 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Carlino MS , GowrishankarK , SaundersCAet al. Antiproliferative effects of continued mitogen-activated protein kinase pathway inhibition following acquired resistance to BRAF and/or MEK inhibition in melanoma . Mol. Cancer Ther.12 ( 7 ), 1332 – 1342 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Das Thakur M , SalangsangF , LandmanASet al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance . Nature494 ( 7436 ), 251 – 255 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Chan MMK , HayduLE , MenziesAMet al. The nature and management of metastatic melanoma after progression on BRAF inhibitors: effects of extended BRAF inhibition . Cancer120 ( 20 ), 3142 – 3153 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Rutkowski P , BlankC . Dabrafenib for the treatment of BRAF V600-positive melanoma: a safety evaluation . Expert Opin. Drug Saf.13 ( 9 ), 1249 – 1258 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Larkin J , Del VecchioM , AsciertoPet al. Vemurafenib in patients with BRAFV600 mutated metastatic melanoma: an open-label, multicentre, safety study . Lancet Oncol.15 , 436 – 444 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Anforth RM , BlumettiTCMP , KeffordRF , SharmaR , ScolyerRA , KossardS . Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma . Br. J. Dermatol.167 ( 5 ), 1153 – 1160 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• GlaskoSmithKline . Tafinlar: adverse reaction managment . https://hcp.gsk.co.uk
   Google Scholar
• Gibney GT , MessinaJL , FedorenkoIV , SondakVK , SmalleyKSM . Paradoxical oncogenesis and the long term consequences of BRAF inhibition in melanoma . Nat. Rev. Clin. Oncol.10 ( 7 ), 390 – 399 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Babacan T , UrkbeylerIHT , BalakanO , PehlivanY , SunerA , KisacikB . A case of vemurafenib-induced polyarhritis in a patient with melanoma: how to manage it?Int. J. Rheum. Dis. doi:10.1111/1756-185X.12396 ( 2014 ) ( Epub ahead of print ).
   PubMedGoogle Scholar
• Trinh VA , DavisJE , AndersonJE , KimKB . Dabrafenib therapy for advanced melanoma . Ann. Pharmacother.48 ( 4 ), 519 – 529 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• McArthur GA , PuzanovI , AmaravadiRet al. Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma . J. Clin. Oncol.30 ( 14 ), 1628 – 1634 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Lexicomp Online® . Lexi-Interact™ Dabrafenib .
   Google Scholar
• Long GV , FungC , MenziesAMet al. Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAF-mutant metastatic melanoma . Nat. Commun.5 , 5694 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Poulikakos PI , PersaudY , JanakiramanMet al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAFV600E . Nature480 ( 7377 ), 387 – 390 ( 2011 ).
   PubMed Web of Science ®Google Scholar
• Girotti MR , MaraisR . Déjà vu: EGF receptors drive resistance to BRAF inhibitors . Cancer Discov.3 ( 5 ), 487 – 490 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Girotti MR , PedersenM , Sanchez-LaordenBet al. Inhibiting EGF receptor or SRC family kinase signaling overcomes BRAF inhibitor resistance in melanoma . Cancer Discov.3 ( 2 ), 158 – 167 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Shi H , HugoW , KongXet al. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy . Cancer Discov.4 ( 1 ), 80 – 93 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Shi H , HongA , KongXet al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition . Cancer Discov.4 ( 1 ), 69 – 79 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Seghers AC , WilgenhofS , LebbéC , NeynsB . Successful rechallenge in two patients with BRAF-V600-mutant melanoma who experienced previous progression during treatment with a selective BRAF inhibitor . Melanoma Res.22 , 466 – 472 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Girotti MR , LopesF , PreeceNet al. Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma . Cancer Cell27 ( 1 ), 85 – 96 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Samatar AA , PoulikakosPI . Targeting RAS–ERK signalling in cancer: promises and challenges . Nat. Rev. Drug Discov.13 ( 12 ), 928 – 942 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Carlino MS , ToddJR , GowrishankarKet al. Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma . Mol. Oncol.8 ( 3 ), 544 – 554 ( 2014 ).
   PubMed Web of Science ®Google Scholar
• Vanneman M , DranoffG . Combining immunotherapy and targeted therapies in cancer treatment . Nat. Rev. Cancer12 ( 4 ), 237 – 251 ( 2012 ).
   PubMed Web of Science ®Google Scholar
• Ribas A , HodiFS , CallahanM , KontoC , WolchokJ . Hepatotoxicity with combination of vemurafenib and ipilimumab . N. Engl. J. Med.368 ( 14 ), 1365 – 1366 ( 2013 ).
   PubMed Web of Science ®Google Scholar
• Puzanov I , CallahanMK , LinetteGP , PatelSP . Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation-positive unresectable or metastatic melanoma (MM) . 2014 ASCO Annual Meeting AbstractsJ. Clin. Oncol.32 ( 5s Suppl. ), Abstract 2511 ( 2014 ).
   PubMedGoogle Scholar
• Ascierto PA , SimeoneE , GiannarelliD , GrimaldiAM , RomanoA , MozzilloN . Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use . J. Transl. Med.10 , 107 ( 2012 ).
   PubMed Web of Science ®Google Scholar